The use of defibrotide in blood and marrow transplantation

Slides:



Advertisements
Similar presentations
PRINCIPLES OF INNATE IMMUNITY
Advertisements

Acquired Immune Response Sanjaya Adikari Department of Anatomy.
Pathophysiology of veno-occlusive disease
Chemical Mediators of Inflammation
Immune System Overview. GOT DEFENSE? ANATOMY OF THE IMMUNE SYSTEM The immune system is localized in several parts of the body –immune cells develop.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Copyright © 2003 American Medical Association. All rights reserved.
Figure Legend: From: Immune Modulation by Volatile Anesthetics
Myeloma cell interaction with extracellular matrix (ECM) and accessory cells in the marrow. Myeloma cells require support from bone marrow stromal cells.
Volume 151, Issue 5, Pages (November 2016)
GVHD-associated immunodeficiency: soil or seed?
Other Cells of Immune System
Figure 3 Neutrophils in liver inflammation
Figure 3 Extracellular stimuli to HSC activation
Carmen Peralta, Mónica B. Jiménez-Castro, Jordi Gracia-Sancho 
Chemical Mediators Dr Shoaib Raza.
by William C. Aird Blood Volume 101(10): May 15, 2003
The Hematologic System as a Marker of Organ Dysfunction in Sepsis
Liver regeneration Journal of Hepatology
Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.
Chlamydophila pneumoniae
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Oncology Meets Immunology: The Cancer-Immunity Cycle
Sleeping sickness Clinical Microbiology and Infection
Figure 1 Immune mechanisms in liver homeostasis
Volume 49, Issue 5, Pages (November 2008)
Coagulation and innate immune responses: can we view them separately?
Vascular endothelial dysfunction in cirrhosis
Malaria Vaccine Design: Immunological Considerations
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Figure 3 The mechanism of injury in ACLF
Postmortem and ex vivo carbon monoxide ventilation reduces injury in rat lungs transplanted from non–heart-beating donors  Boming Dong, MD, PhD, Paul.
Figure 2 Altered innate immune functions after sepsis
Figure 4 Macrophages in liver inflammation
From immunosuppression to tolerance
Activity of eltrombopag in severe aplastic anemia
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Targets for immunotherapy of liver cancer
Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation  David Nachbaur, Petra Schumacher,
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
The yin and yang of evasion and immune activation in HCC
The intrarenal renin-angiotensin system in hypertension
Sinusoidal communication in liver fibrosis and regeneration
Carmen Peralta, Mónica B. Jiménez-Castro, Jordi Gracia-Sancho 
Hypoxia-inducible factor pathway and diseases of the vascular wall
Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions  Batya B. Davidovici, Naveed Sattar,
Advances in the Treatment of Sickle Cell Disease
Thrombosis and Inflammatory Bowel Disease
Volume 66, Issue 1, Pages (January 2017)
The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.
Volume 81, Issue 12, Pages (June 2012)
Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized,
Juan-Carlos García-Pagán, Jorge Gracia-Sancho, Jaume Bosch 
Liver fibrosis – from bench to bedside
Adiponectin: an enlarging role in acute kidney injury
Immunotherapy for Lung Cancer
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program  Selim Corbacioglu, Enric.
Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International.
by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A
Figure 2 Immune changes in peripheral blood of pregnant patients with NMO Immune changes in peripheral blood of pregnant patients with NMO (A) Interleukin.
Adel Hammoutene, Pierre-Emmanuel Rautou  Journal of Hepatology 
Protective strategies against ischemic injury of the liver
Clinical Gastroenterology and Hepatology
Mechanisms of virus-induced airway inflammation in chronic obstructive pulmonary disease (COPD). Mechanisms of virus-induced airway inflammation in chronic.
Fig. 5. (A) The effect of PKA and PI3K inhibitors on VEGF production in NPDFs. KT5720 and LY significantly decreased VEGF production. (B) The effect.
Fig. 4. (A) The effect of PGE2 on cAMP release
HUS and atypical HUS by T. Sakari Jokiranta Blood
Coagulation cascade influenced by renal dysfunction and mechanisms of action of oral anticoagulants. Coagulation cascade influenced by renal dysfunction.
Overall survival of systemic mastocytosis patients.
Toll-like receptors, adapter proteins, and signaling molecules.
Presentation transcript:

The use of defibrotide in blood and marrow transplantation by Paul G. Richardson, Enric Carreras, Massimo Iacobelli, and Bijan Nejadnik BloodAdv Volume 2(12):1495-1509 June 26, 2018 © 2018 by The American Society of Hematology

Proposed pharmacologic actions of defibrotide. Proposed pharmacologic actions of defibrotide. Factors involved in coagulation are depicted in yellow, factors released from endothelial cells are in the green area, factors involved in endothelial cell activation are in the orange area, and factors involved in platelet activation are in the purple area. Yellow circle with red center, inhibition, increase (+) or decrease (–); green arrow, activation; red arrow, production. cAMP, cyclic adenosine monophosphate; CysLT, cysteinyl leukotriene; FPA, fibrinogen peptide A; ICAM, intracellular adhesion molecule; IL-6, interleukin 6; LFA1, leukocyte function-associated antigen 1; LTB4, antileukotriene B4; MHC, major histocompatibility complex; NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells; NO, nitric oxide; NOS, nitric oxide synthase; PAI-1, plasminogen activator inhibitor-1; PAF, platelet-activating factor; PGE2, prostaglandin E2; PGI2, prostaglandin I2; TFPI, tissue factor pathway inhibitor; TM, thrombomodulin; TNFα, tumor necrosis factor-α; TXA2, thromboxane A2; VEGF, vascular endothelial growth factor. Reprinted from Pescador et al2 with permission. Paul G. Richardson et al. Blood Adv 2018;2:1495-1509 © 2018 by The American Society of Hematology

Anatomy of the hepatic sinusoid. Anatomy of the hepatic sinusoid. The hepatic sinusoids are lined by a population of microvascular LSECs that separate hepatocytes and stellate cells from leukocytes circulating through the liver in the blood. Fenestrations in the LSEC lining allow the passive exchange of molecules between the space of Dissé and the blood, as well as direct contact of lymphocyte filopodia with hepatocyte microvilli. The liver interstitium is highly enriched in cells of the innate immune system (such as antigen-presenting dendritic, Kupffer, natural killer, and NKT cells [not shown]) and in T cells, which participate in adaptive immune responses. Mediators produced by both parenchymal and nonparenchymal cells, including IL-10, TGFβ, arginase, and PGE2, regulate immune function within the liver. LSEC, liver sinusoidal endothelial cells; TGFβ, transforming growth factor-β. Reprinted from Thomson et al91 with permission. Paul G. Richardson et al. Blood Adv 2018;2:1495-1509 © 2018 by The American Society of Hematology

Primary end points of phase 3 study in defibrotide-treated patients vs historical controls receiving supportive treatment. Primary end points of phase 3 study in defibrotide-treated patients vs historical controls receiving supportive treatment. (A) Kaplan-Meier estimates of overall survival distribution and (B) complete response (defined as total bilirubin <2 mg/dL and resolution of MOD/MOF) at day +100 following HSCT. Reprinted from Richardson et al70 with permission. Paul G. Richardson et al. Blood Adv 2018;2:1495-1509 © 2018 by The American Society of Hematology